Introduction {#Sec1}
============

In consideration of the different forms of inositol hexakisphosphate identified in soils: 1D-*chiro*-, *myo*-, *neo*- and *scyllo*- ((Anderson [@CR2]; Anderson and Malcolm [@CR3]; Baker [@CR4], cited in Turner et al. [@CR65]; Cosgrove [@CR11], [@CR12], [@CR13], [@CR14], [@CR15]; Cosgrove and Tate [@CR20]; Halstead and Anderson [@CR26]; L'Annunziata [@CR38]; L'Annunziata and Fuller [@CR39]; L'Annunziata et al. [@CR41]; reviewed, Cosgrove [@CR19]); Irving and Cosgrove [@CR32]), it remains unclear what the biotic or abiotic origins of D-*chiro*-, *neo*- and *scyllo*-inositol phosphates are (L'Annunziata [@CR42]; Turner and Richardson [@CR64]; Turner et al. [@CR65]). A limited number of studies have shown biotic contribution to the epimerization of unsubstituted inositols (Cosgrove [@CR15]; L'Annunziata [@CR38]; L'Annunziata and Gonzalez [@CR40] (reviewed L\'Annunziata [@CR42])), or have shown that chemical, and hence, geochemical, epimerization of *myo*-inositol pentakisphosphate is possible (Cosgrove [@CR17]). It is clear from the foregoing that studies of soil phosphate transformations, particularly those arising from input of *myo*-inositol hexakisphosphate from plant sources, would be greatly enabled by the provision of ^32^P or ^33^P-labelled *myo*-inositol hexakisphosphate, and, indeed, of other inositol hexakisphosphates. Such materials would, with established extraction and separation techniques, allow facile determination of the exchange of phosphate between organic and inorganic pools and, with appropriate separation techniques, would allow study of transformations of different isomers of inositol hexakisphosphate. With labelled inositol hexakisphosphates and an increasing literature on the 'pathways' of *myo*-inositol hexakisphosphate degradation by phytases of different classes; cysteine phytase, histidine acid phytase, purple-acid phytase, β-propeller phytase (Konietzny and Greiner [@CR37]), it would be possible to begin to describe 'pathways' of inositol hexakisphosphate turnover in soils and the contribution of different organisms to that turnover.

With these thoughts in mind, we have sought to synthesize ^32^P-labeled inositol hexakisphosphates by enzymic means. We have taken opportunity of a recombinant inositol pentakisphosphate 2-kinase (IP5 2-K, also known as IPK1) characterized (Banos-Sanz et al. [@CR5]; Gonzalez et al. [@CR24]; Gosein and Miller [@CR25]; Sweetman et al. [@CR60]). This enzyme transfers the gamma-phosphate) from ATP to the sole axial hydroxyl on carbon 2 of *myo*-inositol phosphates, and is believed to be the enzyme responsible for synthesis of *myo*-inositol hexakisphosphate in all kingdoms that make this molecule. We reasoned that the enzyme might be capable of transferring phosphate from ATP to the axial hydroxyl(s) of other inositols bearing equatorial phosphates.

The structures of the different inositol 'parents' of the inositol phosphates used in this study are shown in Fig. [1](#Fig1){ref-type="fig"}. The rules for numbering of carbon atoms, and hence of inositol phosphates bearing phosphate substituents on particular carbons are given in the IUPAC-IUB rules (IUPAC-IUB [@CR34], [@CR35]). For *myo*-inositol phosphates, only, a relaxation of the rules (NC-IUB [@CR33]) allows numbering of carbons by the D- (1D) or L- (1L) nomenclature, e.g. to assist in delineating metabolic sequences. The 1D- and 1L- numbering of *myo*-inositol is shown in Fig. [1](#Fig1){ref-type="fig"}. Supplemental Fig. [1](#Fig7){ref-type="supplementary-material"} shows symmetry aspects of the 'parent' inositols of the *myo*-, *neo*-, 1D-*chiro*- and *scyllo*-inositol phosphates discussed hereafter, while Supplemental Fig. [2](#Fig8){ref-type="supplementary-material"} shows the structures of the substrates and products obtained therefrom.Fig. 1The structures of *myo*-, *neo*- *scyllo*- and 1D--*chiro*-inositols. The projections shown left to right are a Mills projection, a Haworth projection and a three-dimensional structure. Carbon atoms in the ring are numbered according to the IUPAC/IUPAC-IUB recommendations ([@CR34], [@CR35]). For *myo*-inositol, both 1L- (upper) and 1D- (lower) notation is shown

For the assistance of researchers wishing to adopt these methods, we provide (Table [1](#Tab1){ref-type="table"}) a summary of the methodologies used with an indication of their applicability and a reference to prior use of the method. We also list the figures in this manuscript in which the method is applied.Table 1Summary of methods of this study and their application to the study of inositol phosphate metabolismSubjectMethodCommentDescription/UseReferenceStereochemistry of inositol phosphatesA comprehensive review of inositol (phosphate) chemistry and stereochemistryFig. [1](#Fig1){ref-type="fig"}Thomas et al. [@CR62]Source of inositol phosphatesComplete synthesis or extracted from soilsThe soil extracted inositol phosphates were the kind gift of Alan Richardson (CSIRO) from the personal stocks of the late Dennis Cosgrove, or were provided by Max Tate (The University of Adelaide)Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, and [6](#Fig6){ref-type="fig"}; Suppl. Fig. [1](#Fig1){ref-type="fig"}Diogenous [@CR22]; Liu et al. [@CR45], [@CR46]; Riley et al. [@CR55]; Turner et al. [@CR66]; Godage et al. [@CR23]; collected works of Cosgrove, Tate and others (reviewed this manuscript)Source of synthetic enzymeFigs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, and [6](#Fig6){ref-type="fig"}; Suppl. Fig. [1](#Fig1){ref-type="fig"}Sweetman et al. [@CR60]Non-radioactive verification of enzyme specificityReverse-phase ion-pair chromatography with UV detection of nucleotidesUsed to titrate enzyme concentration before use of radiolabelFig. [2](#Fig2){ref-type="fig"}Caddick et al. [@CR10]Production of ^32^P--labeled inositol phosphatesAnion-exchange chromatography on Partisphere SAX columns with on-line detection by Cerenkov countingUsed to separate/verify reaction productsFig. [3](#Fig3){ref-type="fig"}Brearley and Hanke [@CR8]a, b; Nagy et al. [@CR50]; Stephens [@CR58]Substrate specificity/product profiles of different phytasesAnion-exchange chromatography on Partisphere SAX columns with on-line detection by Cerenkov countingCan be used to separate/purify particular isomersFig. [4](#Fig4){ref-type="fig"}Stentz et al. [@CR57]Non radioactive detection of inositol phosphates on acid gradients with UV detectionAnion exchange chromatography on CarboPac PA200 columns with post-column addition of ferric nitrateA particularly robust separation method for higher inositol phosphates using volatile (HCl) or non-volatile (methanesulfonic) acid eluents. Could be combined with Cerenkov counting for radiolabeled inositol phosphatesFig. [5](#Fig5){ref-type="fig"}Phillippy and Bland [@CR53]; Blaabjerg et al. [@CR7]Non radioactive detection of pentakisphosphates that can be generated from soil inositol hexakisphosphatesAnion exchange chromatography on CarboPac PA200 columns with post-column addition of ferric nitrateA particularly robust separation method for higher inositol phosphates using volatile (HCl) or non-volatile (methanesulfonic) acid eluents. Could be combined with Cerenkov counting for radiolabeled inositol phosphatesFig. [6](#Fig6){ref-type="fig"}This manuscriptThe structures of substrates and products of *At*IP5 2 KSuppl. Fig. [1](#Fig1){ref-type="fig"}This manuscript

Methods {#Sec2}
=======

Inositol phosphate substrates {#Sec3}
-----------------------------

The synthesis of *neo*-inositol 1,3,4,6-tetrakisphosphate (*neo*-Ins(1,3,4,6)P~4~), 1D-*chiro*-inositol 1,3,4,6-tetrakisphosphate (1D-*chiro*-Ins(1,3,4,6)P~4~), 1D-*chiro*-inositol 2,3,4,5-tetrakisphosphate (1D-*chiro*-Ins(2,3,4,5)P~4~), *myo*-inositol 1,3,4,5,6-pentakisphosphate (*myo*-Ins(1,3,4,5,6)P~5~), *scyllo*-inositol pentakisphosphate and of *neo*- and 1D-*chiro* inositol hexakisphosphates was described (Diogenous [@CR22]; Liu et al. [@CR45]; Liu et al. [@CR46]; Godage et al. [@CR23]; Riley et al. [@CR55]; Turner et al. [@CR66])). *Myo*-inositol hexakisphosphate was obtained from Merck Millipore (Product No. 407125).

Radioisotopes {#Sec4}
-------------

ATP, \[γ-^32^P\]- 3000 Ci mmol^−1^ was obtained from PerkinElmer.

Cloning and expression of AtIPK1 {#Sec5}
--------------------------------

*Arabidopsis thaliana IPK1* (AGI number): At5G42810, was cloned from *Arabidopsis thaliana* Col-0 cDNA with forward primer *AAGTTCGTTTTCAGGGCCCG*ATGGAGATGATTTTGGAGGAGAA and reverse primer *ATGGTCTAGAAAGCTTTA*GCTGTGGGAAGGTTTTG (vector specific sequence in italics) using Phusion High Fidelity Polymerase (Thermo Scientific). Purified product (Wizard SV Gel and PCR Cleanup System, Promega) was inserted into pOPINF linearized with HindIII and KpnI (Berrow et al. [@CR6]) by ligation independent cloning using In Fusion HD enzyme kit (Clontech). The vector adds a *N*-terminal hexahistidine tag to the recombinant protein. Recombinant plasmid was transformed into *E coli* Rosetta (DE3) (Novagen) and protein production induced from an overnight culture grown in LB containing 0.5% (*w*/*v*) glucose and ampicillin by transfer to LB containing 0.5 mM IPTG and ampicillin with further growth for 7 h at 25 °C.

Protein purification {#Sec6}
--------------------

*At*IPK1 was purified according to (Banos-Sanz et al. [@CR5]).

Enzyme assays {#Sec7}
-------------

For assays without radiolabel, inositol phosphate-dependent conversion of ATP to ADP was followed by reverse-phase ion pair HPLC and subsequent detection of nucleotides at 260 nm (Caddick et al. [@CR10]). Briefly, 1 μg enzyme was incubated with 500 μM inositol phosphate and 50 μM ATP in 20 mM HEPES, pH 7.3, 1 mM MgCl~2~ for 2 h at 25 °C, the volume of the assay was 20 μL. Reactions were terminated by the addition of 1 μL of conc. HCl, followed after 5 min on ice by the addition of 50 μL water. Aliquots (50 μL) were analysed by HPLC.

For assays with radiolabel, ATP-dependent conversion of inositol phosphates to higher (more phosphorylated) species was followed by anion-exchange HPLC with on-line detection of ^32^P. Briefly, 1 μg enzyme was incubated with 500 μM inositol phosphate and 5 μM ATP in the presence of 0.37 MBq \[γ-^32^P\]ATP in 20 mM HEPES, pH 7.3, 1 mM MgCl~2~ for 1 h at 25 °C, the volume of the assay was 20 μL. The reaction products were diluted with water and approximately 1--5% of the products were analysed by HPLC.

HPLC separation of inositol phosphates {#Sec8}
--------------------------------------

Radiolabeled inositol phosphates were separated by anion exchange HPLC on Partisphere SAX columns eluted at a flow rate of 1 mL min^−1^ with a gradient derived by mixing solvent from reservoirs containing (A) water and (B) 1.25 M (NH~4~)~2~HPO~4~, adjusted to pH 3.8 with H~3~PO~4~, according to the following schedule: time (min), % B; 0, 0; 5, 0; 65, 100. Radioactivity was detected by Cerenkov counting in a Radiomatic A500 Series Flo Detector (Canberra Packard, Pangbourne, Bucks, UK) fitted with a 0.5 ml flow cell using an integration interval of 12 s (Hanke et al. [@CR27]).

Non-labelled inositol phosphates were resolved by anion exchange HPLC on a 250 × 3 mm i.d. CarboPac PA200 column (Dionex UK, Ltd) and guard column 50 × 3 mm of the same material, eluted at a flow rate of 0.4 mL min^−1^ with gradients of either HCl or methanesulfonic acid (Blaabjerg et al. [@CR7]). Inositol phosphates were detected after post-column addition of 0.1% (*w*/*v*) ferric nitrate in 2% HClO~4~ (Phillippy and Bland [@CR53]) delivered at a flow rate of 0.2 mL min^−1^. The gradient for both eluents was (A) water, (B) 0.6 M acid: time (min), % B; 0, 0; 25, 100; 38, 100.

HPLC separation of nucleotides {#Sec9}
------------------------------

Aliquots of the products of enzyme assays were analysed according to (Caddick et al. [@CR10]).

Nomenclature {#Sec10}
------------

For the purpose of this article, the term 'Ins' with prefix 1D-*chiro*-, *myo*-, *neo*- or *scyllo*- is used as an abbreviation of the described inositol phosphate. Hence, *neo*-inositol 1,3,4,6-tetrakisphosphate is abbreviated *neo*-Ins(1,3,4,6)*P* ~4~. It should be noted, however, that the numbering of phosphate substituents (of the carbon atoms to which they are attached) is not necessarily the same for different stereoisomers of inositol. The reader is referred to Shears and Turner ([@CR56]) for a concise description of terminology and to (Thomas et al. [@CR62]) for a comprehensive review of inositol and inositol phosphate nomenclature and terminology.

Results {#Sec11}
=======

*At*IP5 2-K can be used to synthesize a range of inositol phosphate epimers, verifiable by non-radioactive assay of inositol phosphate production

We have previously described the use of *At*IP5 2-K to synthesize *myo*-Ins(1,\[^32^P\]2,3,4,5,6)*P* ~6~ from \[γ-^32^P\]ATP and *myo*-Ins(1,3,4,5,6)*P* ~5~ (Nagy et al. [@CR50]). Here, we have further examined the ability of *At*IP5-2 K to phosphorylate *myo*-Ins(1,3,4,6)*P* ~4~. We did so, not only because *myo*-Ins(1,3,4,6)*P* ~4~ possesses an axial 2-OH, but also because of the availability of the *neo*-inositol epimer, *neo*-Ins(1,3,4,6)*P* ~4~ (Diogenous [@CR22]). This inositol phosphate shares the plane of symmetry that bisects the *myo*-Ins(1,3,4,6)*P* ~4~ molecule between C2 and C5, but also possesses a second axial hydroxyl on C5 which creates a *C* ~2~-axis of rotational symmetry that bisects the C1-C6 bond and the C3-C4 bond (Supplementary Figure [1](#Fig7){ref-type="supplementary-material"}). The consequence of this is that single phosphorylation of C2 generates the same product as phosphorylation of C5, while in contrast phosphorylation of C2 of *myo*-Ins(1,3,4,6)*P* ~4~ is not equivalent to phosphorylation of C5.

We incubated *At*IP5 2-K with 500 μM inositol phosphate and 50 μM ATP. The products were resolved by reverse-phase ion-pair HPLC with detection of nucleotides at 260 nm (Fig. [2](#Fig2){ref-type="fig"}). Peak areas were integrated and the % of the nucleotide converted to ADP was calculated. A control incubation without inositol phosphate confirmed that *At*IP5 2-K is not a phosphatase; the 1.3% of nucleotide recovered as ADP is typical of the level of contamination of commercial ATP with ADP (Fig. [2a](#Fig2){ref-type="fig"}). Inclusion of *myo*-Ins(1,3,4,6)*P* ~4~ increased ADP production, 12.1% of total nucleotide was recovered as ADP, without production of AMP (Fig. [2b](#Fig2){ref-type="fig"}), whereas for the physiological substrate *myo*-Ins(1,3,4,5,6)*P* ~5~, included at 50 μM, 26% of nucleotide was recovered as ADP (Fig. [2c](#Fig2){ref-type="fig"}). Clearly, *myo*-Ins(1,3,4,6)P~4~ is a substrate, albeit a poorer one than *myo*-Ins(1,3,4,5,6)*P* ~5~. In contrast, *neo*-Ins(1,3,4,6)*P* ~4~ was a strong substrate with ADP production at 90.8% (Fig. [2d](#Fig2){ref-type="fig"}).Fig. 2Phosphotransferase reactions catalysed by AtIP5 2-K. The nucleotide products of reactions of enzyme, ATP and different inositol phosphates were separated by ion-pair RP-HPLC and detected by absorbance at 260 nm. **a** no inositol phosphate; **b** *myo*-Ins(1,3,4,6)*P* ~4~; **c** *myo*-Ins(1,3,4,5,6)*P* ~5~; **d** *neo*-Ins(1,3,4,6)*P* ~4~; **e** 1D--*chiro*-Ins(2,3,4,5)*P* ~4~; **f** 1D--*chiro*-Ins(1,3,4,6)*P* ~4~

Similarly, inclusion of 1D-*chiro*-Ins(2,3,4,5)*P* ~4~ at 500 μM resulted in 92% conversion of ATP to ADP (Fig. [2e](#Fig2){ref-type="fig"}), while 1D-*chiro*-Ins(1,3,4,6)*P* ~4~ whose two hydroxyls, on C2 and C5 are equatorial (Supplementary Figure [1](#Fig7){ref-type="supplementary-material"}) was not a substrate for *At*IP5 2-K, with ADP representing 1.5% of the total nucleotide (Fig. [2f](#Fig2){ref-type="fig"}).

These results confirm the utility of *neo*-Ins(1,3,4,6)*P* ~4~ and 1D-*chiro*-Ins(2,3,4,5)*P* ~4~ as substrates from which higher *neo*- and 1D-*chiro*-inositol phosphates can be synthesized with *At*IP5 2-K. They further confirm the exclusive phosphorylation of axial hydroxyls by this enzyme (Gonzalez et al. [@CR24]; Sweetman et al. [@CR60]).

We additionally tested racemic mixtures of 1D/L-*neo*-Ins(1,2,4)*P* ~3~ and 1D/L -*neo*-Ins(1,3,4)*P* ~3~ as substrates in extended (16 h) incubations at 500 μM concentration with 50 μM ATP. We did not observe production of ADP, thus these molecules are not substrates despite possessing one and two axial hydroxyls at C5, and C2 and C5 respectively (data not shown).

*At*IP5 2-K can be used to synthesize a range of ^32^P-labeled inositol phosphates {#Sec12}
----------------------------------------------------------------------------------

Having established that *neo*-Ins(1,3,4,6)*P* ~4~ and 1D-*chiro*-Ins(2,3,4,5)*P* ~4~ are novel substrates of *At*IP5 2 K, we performed enzyme assays to produce ^32^P-labelled inositol phosphates. The substrate concentrations used were 500 μM inositol phosphate and 5 μM ATP. Reactions were terminated and the products spiked with additional ATP to allow online tandem UV-radioactivity monitoring of the chromatography (Fig. [3](#Fig3){ref-type="fig"}). We included *myo*-Ins(1,3,4,5,6)*P* ~5~ as the canonical substrate and observed (Fig. [3a](#Fig3){ref-type="fig"}) in addition to a major peak of *myo*-Ins*P* ~6~ eluting at a retention time of 55 min, a small peak of unidentified material eluting at 38.8 min, a major peak of unreacted ATP at 25.2 min and a peak of inorganic phosphate at 14.6 min. We note that others have reported impurities in commercial \[^32^P\]ATP that elute on Partisphere SAX columns with similar chromatographic mobility to *myo*-Ins*P* ~4~s (Stephens [@CR58]).Fig. 3Synthesis of ^32^P-labelled inositol phosphates with AtIP5 2-K. The inositol phosphate products of reactions of enzyme, \[^32^P\]ATP and different inositol phosphates were separated by Partisphere Strong Anion Exchange HPLC and radioactivity estimated by on-line Cerenkov counting. **a** *myo*-Ins(1,3,4,5,6)*P* ~5~; **b** *neo*-Ins(1,3,4,6)*P* ~4~; **c** 1D--*chiro*-Ins(1,3,4,6)*P* ~4~, **d** 1D--*chiro*-Ins(2,3,4,5)*P* ~4~. The peaks labelled are the ^32^P labelled products or reactants (ATP)

Provision of *neo*-Ins(1,3,4,6)*P* ~4~ as substrate yielded (Fig. [3b](#Fig3){ref-type="fig"}) a major peak of label with the chromatographic property of Ins*P* ~5~ at 46.4 min and a more polar (highly charged peak) with the chromatographic property of an Ins*P* ~6~. This peak eluted at 56.4 min, slightly after *myo*-Ins*P* ~6~. The trace also showed peaks of assumed impurity, ATP and inorganic phosphate. Considering the structure of *neo*-Ins(1,3,4,6)*P* ~4~ and its *C* ~2~ axis of rotational symmetry (Supplemental Figs. [1](#Fig7){ref-type="supplementary-material"}, [2](#Fig8){ref-type="supplementary-material"}), the two axial hydroxyls are superposable so there is only one possible Ins*P* ~5~ product. IUPAC conventions recommend the naming of substituents by the lowest numbered locants, hence single phosphorylation of one axial hydroxyl of *neo*-Ins(1,3,4,6)*P* ~4~ yields *neo*-Ins(1,2,3,4,6)*P* ~5~ = *neo*-Ins(1,3,4,5,6)*P* ~5~ with preferred use of the former name. The addition of ^32^P to an unlabeled substrate therefore yields *neo*-Ins(1,\[^32^P\]2,3,4,6)*P* ~5~. The elution of a second more polar peak, we assume to represent the double phosphorylation of *neo*-Ins(1,3,4,6)*P* ~4~ to give *neo*-Ins(1,\[^32^P\]2,3,4,\[^32^P\]5,6)*P* ~6~.

We also tested 1D-*chiro*-Ins(1,3,4,6)*P* ~4~ and 1D-*chiro*-Ins(2,3,4,5)*P* ~4~ as co-substrates with \[^32^P\]ATP (Fig. [3c](#Fig3){ref-type="fig"}, d). Significantly, the former, which bears equatorial hydroxyls on C2 and C5, and lacks axial hydroxyls (Fig. [1](#Fig1){ref-type="fig"}; Supplemental Figs. [1](#Fig7){ref-type="supplementary-material"}, [2](#Fig8){ref-type="supplementary-material"}), was not a substrate and yielded peaks of unreacted ATP, inorganic phosphate and the assumed contaminant with retention time 39 min (Fig. [3c](#Fig3){ref-type="fig"}). In contrast, 1D-*chiro*-Ins(2,3,4,5)*P* ~4~, like *neo*-Ins(1,3,4,6)*P* ~4~, yielded ^32^P-labeled peaks with the chromatographic mobility of Ins*P* ~5~, retention time 48 min; and Ins*P* ~6~, retention time 59.5 min (Fig. [3d](#Fig3){ref-type="fig"}). Comparison of the retention time of peaks of Ins*P* ~5~ and Ins*P* ~6~ products (Fig. [3a--d](#Fig3){ref-type="fig"}) reveals that the Ins*P* ~5~ and Ins*P* ~6~ products of different epimers of inositol (tetrakisphosphate) are chromatographically distinct. Again, 1D-*chiro*-Ins(2,3,4,5)*P* ~4~, another substrate with two axial hydroxyls, yielded products which, relative to the substrate, were singly and doubly phosphorylated by AtIP5 2-K. Moreover, 1D-*chiro*-Ins(2,3,4,5)*P* ~4~ possesses a *C* ~2~-axis of symmetry, here bisecting the C1-C6 and C3-C4 bonds, which superposes C1 and C2 substituents. Consequently, a common Ins*P* ~5~ product is generated from phosphorylation of either axial hydroxyl and the product is 1D-*chiro*-Ins(1,2,3,4,5)*P* ~5~, here 1D-*chiro*-Ins(\[^32^P\]1,2,3,4,5)*P* ~5~. The Ins*P* ~6~ product is 1D-*chiro*-Ins(\[^32^P\]1,2,3,4,5,\[^32^P\]6)*P* ~6~.

Different phytases yield characteristic product profiles from ^32^P-labeled *myo*-inositol hexakisphosphate {#Sec13}
-----------------------------------------------------------------------------------------------------------

By way of illustration of how different phytases yield different product profiles from the same substrate, we show (Fig. [4](#Fig4){ref-type="fig"}) the products of progressive dephosphorylation of *myo*-Ins(1,\[^32^P\]2,3,4,5,6)*P* ~6~ by histidine acid phytases of fungal and bacterial origin. We chose *Aspergillus ficuum* phytase, a D-3 phytase (data of Fig. [4c](#Fig4){ref-type="fig"}), where D-3 signifies the position of attack on *myo*-Ins*P* ~6~ and HD is one of the canonical motifs, D (aspartate) being a proton donor that activates a water molecule that is responsible for the cleavage of scissile phosphate. The other phytase (data of Fig. [4b](#Fig4){ref-type="fig"}) is another histidine acid phytase, but is the archetype of a recently described HAE subclass where E (glutamate) is the likely proton donor. This enzyme generates three resolvable Ins*P* ~5~ products from *myo*-Ins*P* ~6~ (Stentz et al. [@CR57]). These data reveal the utility of inositol hexakisphosphate labeled on the axial 2-position for study of phytases in vitro. Clearly, they indicate the potential utility of such compounds and such chromatography for study of soil processes.Fig. 4Separations of ^32^P labelled inositol phosphate products of dephosphorylation of *myo*-Ins(1,\[^32^P\]2,3,4,5,6)*P* ~5~ by HAE (*Bacteroides thetaiotomicron* Minpp) and HD (*Aspergillus niger*) phytases. The products of reactions of **a** no enzyme control; **b** *Bt*Minpp and **c** *A ficuum* phytase were separated by Partisphere Strong Anion Exchange HPLC and radioactivity estimated by on-line Cerenkov counting. The positions of elution of representative classes of *myo*-inositol phosphate products and of contaminating ATP in the *myo*-\[^32^P\]Ins*P* ~6~ preparation are indicated. The difference in retention time of inositol hexakisphosphate between different panels reflects the use of different Partisphere SAX columns for the separations

Separation of inositol hexakisphosphates identified in soils {#Sec14}
------------------------------------------------------------

Using the post-column complexation method (Phillippy and Bland [@CR53]) and a CarboPac PA-200 column eluted with a gradient of HCl, we were able to resolve in order of increasing retention time, *neo*-Ins*P* ~6~, *muco*-Ins*P* ~6~, 1D-*chiro*-Ins*P* ~6~, *myo*-Ins*P* ~6~ and *scyllo*-Ins*P* ~6~ (Fig. [5a](#Fig5){ref-type="fig"}), all samples obtained from the laboratory of the late Dennis Cosgrove. We assume that the *muco*-Ins*P* ~6~ was that made by chemical phosphorylation of the inositol (Cosgrove [@CR18]). The gradient shows a strongly sloping baseline arising from the acid eluent and this UV absorbance can be negated when using methanesulfonic acid as the eluent (Blaabjerg et al. [@CR7]); however, at least up to 0.6 M, methanesulfonic acid was not a strong enough eluent to elute *scyllo*-Ins*P* ~6~ from this column.Fig. 5Separations of soil-representative inositol phosphates on a Dionex CarboPac PA200 column. The column was eluted with a gradient of HCl (**a**) or methanesulfonic acid (**b**) and inositol phosphates detected by post-column complexation with ferric nitrate in perchloric acid and subsequent detection at 290 nm. **a**, **b** Inositol phosphates were obtained from the laboratory of the late DJ Cosgrove. **a** the traces from individual injections (approximately 20 nmol) of different inositol hexakisphosphates are offset on the Y-scale to aid visualisation. **b** Samples of individual injections of synthetic *neo*-Ins*P* ~4~ with retention time 16--17 min, *neo*-Ins*P* ~5~ with retention time 21--22 min and *neo*-Ins*P* ~6~ with retention time 26.9 min are overlaid

Separation of *neo*-inositol phosphates {#Sec15}
---------------------------------------

Methanesulfonic acid was, however, suitable for separation of *neo*-Ins*P*s: *neo*-Ins*P* ~4~s, *neo*-Ins*P* ~5~s and *neo*-Ins*P* ~6~ (Fig. [5b](#Fig5){ref-type="fig"}), again, these compounds were likely produced by chemical phosphorylation of *neo*-inositol with sodium trimetaphosphate (Cosgrove [@CR14]). Irving ([@CR29]) reported that *neo*-Ins*P* ~6~ was a good substrate of both the *Pseudomonas* (sp. unknown) bacterium (SB~2~) phytase of Cosgrove (Cosgrove et al. [@CR21]) and *A. ficuum* phytase (Irving and Cosgrove [@CR31]). We note that there are nine possible *neo*-Ins*P* ~4~s, comprised of three pairs of enantiomers and three *meso*-compounds and there are three possible *neo*-Ins*P* ~5~s (Thomas et al. [@CR62]). Of the *neo*-Ins*P* ~5~s, two: 1L-*neo*-Ins(1,2,3,4,5)*P* ~5~ = 1D-*neo*-Ins(1,2,3,5,6)*P* ~5~ and 1D-*neo*-Ins(1,2,3,4,5)*P* ~5~ = 1L-*neo*-Ins(1,2,3,5,6)*P* ~5~ are a pair of enantiomers, the third is the *meso*-compound *neo*-Ins(1,2,3,4,6)*P* ~5~. In the absence of chiral HPLC methods for separating enantiomers of inositol phosphates, the separation of two peaks of *neo*-Ins*P* ~5~ from the Cosgrove samples (Fig. [5b](#Fig5){ref-type="fig"}) is all that is achievable, but nevertheless could be diagnostic in studies of *neo*-Ins*P* ~6~ transformation in soils.

Separation of inositol pentakisphosphates; the initial products of phytase action on inositol hexakisphosphate {#Sec16}
--------------------------------------------------------------------------------------------------------------

Finally, we show (Fig. [6](#Fig6){ref-type="fig"}) the separation of a variety of Ins*P* ~5~s including the four separable peaks of *myo*-Ins*P* ~5~, identified in Fig. [6b](#Fig6){ref-type="fig"} by the position of the single hydroxyl; the two enantiomeric pairs 1D-1/3-OH and 1D-4/6-OH, indicated \[1/3-OH\] and \[4/6-OH\] on the figure, cannot be separated into individual enantiomers on non-chiral HPLC. Figure [6b](#Fig6){ref-type="fig"} also shows the single *scyllo*-Ins*P* ~5~ and several Ins*P* ~5~s present in a 1L-*chiro*-Ins*P* ~5~ sample. There are three possible 1L-*chiro*-Ins*P* ~5~s and, similarly, three possible 1D-*chiro*-Ins*P* ~5~s. Minor *chiro*-Ins*P* ~5~ peaks with common retention times were observed in the 1D-*chiro*-Ins*P* ~6~ sample (Fig. [6a](#Fig6){ref-type="fig"}) and the 1L-*chiro*-Ins*P* ~5~ sample (Fig. [6b](#Fig6){ref-type="fig"}), with two of the three co-eluting precisely with peaks in a 1L-*chiro*-Ins*P* ~5~ sample (Fig. [6a](#Fig6){ref-type="fig"}). Clearly, this column/eluent combination has great resolving power for all the Ins*P* ~5~s expected of soil samples.Fig. 6HPLC separation of soil-representative inositol pentakisphosphates. A Dionex CarboPac PA200 column was eluted with a gradient of methanesulfonic acid. Inositol phosphates were obtained from the laboratory of the late DJ Cosgrove. **a** The traces from individual injections of different inositol phosphate samples: a 1D-*chiro*-Ins*P* ~6~ sample with three 1D-chiro-Ins*P* ~5~s, a 1L-chiro-Ins*P* ~5~ sample with two 1L-*chiro*-Ins*P* ~5~s and a *neo*-Ins*P* ~5~ sample. **b** The traces from individual injections of different inositol phosphate samples: a 1L-*chiro*-Ins*P* ~6~ sample with three 1L-*chiro*-Ins*P* ~5~s, a *scyllo*-Ins*P* ~5~ sample and an acid hydrolysate of *myo*-Ins*P* ~6~ with all four resolvable *myo*-Ins*P* ~5~. **a**, **b** Traces are offset on the Y-scale (left or right) to aid visualisation

Discussion {#Sec17}
==========

Inositol phosphates are major components of total soil phosphate and commonly the dominant organic phosphates in these environments (Turner et al. [@CR65]). Despite their abundance, the origins of *neo*-, 1D-*chiro*- and *scyllo*-inositol hexakisphosphates in soils are poorly defined. It is plausible that they derive from the considerable inputs to soil of plant-derived *myo*-inositol hexakisphosphate, representing up to several percent of seed dry weight (Raboy [@CR54]). It has been estimated that the sequestration of phosphorus in the *myo*-inositol hexakisphosphate, phytate, reserves of cropped organs of plants is equivalent to the per annum application of phosphorus as fertilizer to soils (Lott et al. [@CR47]). It is remarkable therefore that we do not know, how plant-derived phytate is, likely, converted to other forms (epimers) of inositol phosphates, nor whether the processes are organismal or geochemical.

The epimerization of unsubstituted inositols by unsterilized soil is well described (L'Annunziata and Gonzalez [@CR40]) and pathways by which *myo*-inositol and s*cyllo*-inositol are converted have been engineered in *Bacillus subtilis* (Kang et al. [@CR36]; Tanaka et al. [@CR61]; Yamaoka et al. [@CR67]). Similarly, *Geobacillus kaustophilus* HTA426, has three dehydrogenases that are capable of acting as epimerases to interconvert *myo*-, *scyllo*-, and 1D*-chiro*- inositols (Yoshida et al. [@CR68]). The American cockroach*, Periplaneta americana*, was reported to possess epimerase activity producing *neo*-inositol. (Hipps et al. [@CR28]). Plants have the ability to epimerize a number of methylated inositols, reviewed (Thomas et al. [@CR62]). These studies seem to suggest that epimerase activity is restricted to inositols lacking phosphate substituents. It is intriguing therefore that *scyllo*-phosphoinositides were detected in barley (Narasimhan et al. [@CR51]) and that highly phosphorylated inositol phosphates and diphosphoinositol phosphates containing *neo*- rather than *myo*-inositol are the major form of inositol phosphate in *Entamoeba histolytica* (Martin et al. [@CR49]), despite earlier suggestion to the contrary (Martin et al. [@CR48]).

Because the axial 2-phosphate is the last phosphate added in the synthesis of *myo*-inositol hexakisphosphate in plants (Brearley and Hanke [@CR8]) and *Dictyostelium discoideum* (Stephens and Irvine [@CR59]) it is possible to use the enzyme catalyzing this step to make *myo*-inositol 1,\[^32^P\]2,3,4,5,6-hexakisphosphate. Moreover, because most phytases of plant, bacterial or fungal origin do not remove this phosphate until very late in the sequence of *myo*-inositol hexakisphosphate degradation, if at all (Konietzny and Greiner [@CR37]), the ^32^P label will be retained in successive *myo*-Ins*P* ~5~, Ins*P* ~4~, Ins*P* ~3~ and Ins*P* ~2~ products of dephosphorylation. Consequently, addition of ^32^P-labeled *myo*-Ins*P* ~6~ to soils will, by simple chromatography using the methods elaborated here, allow researchers to study *myo*-inositol hexakisphosphate turnover in their soil of choice.

From a practical perspective, the use of a high energy β emitter such as ^32^P allows facile detection of radioactivity in column eluates by on-line Cerenkov counting, obviating the requirement for the addition of scintillation fluid. The use of flow-detectors therefore allows for simple collection of radiolabelled fractions, albeit in high salt concentrations required to elute highly polar inositol phosphates. For phosphate eluents, it is a simple exercise to desalt the collected fractions on Dowex AG1 X8 resin with volatile ammonium formate / formic acid mixtures, subsequently removed by freeze-drying (Stephens [@CR58]; Brearley et al. [@CR9]), while for HCl eluents the HCl can be removed directly by freeze-drying.

From a diagnostic perspective, because different phytases produce different *myo*-Ins*P* ~5~ products (after all, this is the explanation of their classification e.g. as D3, *Aspergillus*; D6, *E.coli* or D5, lily pollen alkaline phytases (Konietzny and Greiner [@CR37])), simple analysis of products at the level of *myo*-Ins*P* ~5~ will allow identification of the likely class of enzyme predominantly responsible for initial degradation of *myo*-Ins*P* ~6~ in different soils. Indeed, it will be fascinating to correlate *myo*-inositol hexakisphosphate degradation products with metagenomic characterization of phytase and micoorganism abundance in different soils of the sort recently described (Neal et al. [@CR52]).

In consideration of the routes of degradation of other inositol hexakisphosphates, the other labeled isomers that we describe will be of particular value. Perhaps unsurprisingly, we note the seminal work of Cosgrove ([@CR14], [@CR16]) and Irving and Cosgrove ([@CR30]) in characterization of products of dephosphorylation of *myo*-inositol-, *scyllo*-inositol-, and 1D-*chiro*-inositol hexakisphosphate by a bacterial phytase, and similar studies of wheat phytase by Lim and Tate ([@CR43], [@CR44]) following the methods of Tomlinson and Ballou ([@CR63]). These works, reviewed (Irving [@CR29]), show that the axial phosphates of *myo*- and 1D-*chiro*-inositol hexakisphosphates are the last to be removed by plant, bacterial and fungal phytases where tested. Similar conclusions can be drawn for fungal phytase action on 1L-*chiro*-inositol hexakisphosphate (Adelt et al. [@CR1]). With these observations in mind, the use of the labeled Ins*P* ~5~ and Ins*P* ~6~ species and the powerful separation approaches identified in the foregoing should allow for facile assessment of the exchange of phosphate between different inositol phosphates in soil contexts.
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Supplemental Figure 1The structures of *myo*-, *neo*- *scyllo*- and 1D-*chiro*-inositols. The projections shown are a Mills projection and a three-dimensional structure. Carbon atoms in the ring are numbered according to the IUPAC/IUPAC-IUB recommendations ([@CR34], [@CR35]). Symmetry elements are shown in the Mills projection: planes of symmetry are indicated by dashed lines marked with an asterisk, rotational axes of symmetry are shown by dashed lines marked with symbol, o. The other dashed lines represent apparent symmetry elements that are not real (Thomas et al. [@CR62]). *Myo*-inositol is shown in 1L- notation. (GIF 125 kb) High resolution image (TIFF 92 kb) Supplemental Figure 2The structures of *myo*-, *neo*- and 1D-*chiro*-inositol phosphate substrates and products of AtIP5 2-K. Three-dimensional structures are shown. Carbon atoms in the ring are numbered according to the IUPAC/IUPAC-IUB recommendations ([@CR34], [@CR35]). A,B, for *myo*-Ins(1,3,4,5,6)*P* ~5~, 1L- notation is used to number the carbons, but note that the product is a *meso*-compound. B, C, D, for *neo*-Ins(1,3,4,6)*P* ~4~, the substrate and products are *meso*-compounds. E, F, G, for D-*chiro*-Ins(2,3,4,5)*P* ~4~, the substrates and products are chiral. (GIF 310 kb) High resolution image (TIFF 2927 kb)
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